Sydney Lepkin
👤 SpeakerAppearances Over Time
Podcast Appearances
Eli Lilly's new pill is called Fundeo.
Although this is the same company behind Zetbound, the blockbuster injectable obesity medicine, Eli Lilly decided not to take Zetbound's main ingredient and make it in pill form.
Instead, the company developed a new ingredient, Orfaglipron.
Daniel Skowronski, the company's chief scientific and medical officer, says until now, all of these GLP-1 drugs have been peptides, meaning they need to be taken as injections or as a pill with restrictions.
Lilly hasn't announced a list price yet, but it says people with commercial insurance could pay as little as $25 a month.
Eli Lilly's new pill is called Fundeo.
Although this is the same company behind Zepbound, the blockbuster injectable obesity medicine, Eli Lilly decided not to take Zepbound's main ingredient and make it in pill form.
Instead, the company developed a new ingredient, Orfaglipron.
Daniel Skowronski, the company's chief scientific and medical officer, says until now, all of these GLP-1 drugs have been peptides, meaning they need to be taken as injections or as a pill with restrictions.
Lilly hasn't announced a list price yet, but it says people with commercial insurance could pay as little as $25 a month, and for people paying cash, the lowest dose will cost $149 a month.
Novo Nordisk will drop its lawsuit against HIMSS.
In exchange, HIMSS will stop advertising its compounded version of Novo Nordisk's Wagovi.
Compounded drugs are made by a specialized pharmacy, not a drug company.
HIMS will continue to offer compounded semaglutide, the active ingredient in Wagovi, but on a more limited scale, it says.
It will also offer brand-name Wagovi injections and pills on its telehealth platform starting later this month.
HIMS launched a compounded version of Novo Nordisk's brand-new weight loss pill in February.
After Novo threatened to sue and federal regulators signaled a crackdown, HIMS said it would drop its copycat pill.